CA2297083C - Compositions pharmaceutiques renfermant de la lysostaphine seule ou en combinaison avec un antibiotique pour le traitement des infections staphylococciques - Google Patents
Compositions pharmaceutiques renfermant de la lysostaphine seule ou en combinaison avec un antibiotique pour le traitement des infections staphylococciques Download PDFInfo
- Publication number
- CA2297083C CA2297083C CA002297083A CA2297083A CA2297083C CA 2297083 C CA2297083 C CA 2297083C CA 002297083 A CA002297083 A CA 002297083A CA 2297083 A CA2297083 A CA 2297083A CA 2297083 C CA2297083 C CA 2297083C
- Authority
- CA
- Canada
- Prior art keywords
- lysostaphin
- infection
- vancomycin
- treatment
- aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24075—Lysostaphin (3.4.24.75)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La lysostaphine est connue pour être un agent antistaphylococcique puissant qui se prête à l'administration parentérale aux mammifères, y compris aux êtres humains. Les faibles dosages, de l'ordre de 0,5-45 mg/kg/jour sont suffisants pour venir à bout de la plupart des infections staphylococciques. La lysostaphine est également efficace contre les bactéries du type considéré qui ont acquis une résistance aux antibiotiques classiques, comme les pénicillines et la vancomycine. Les analogues de la lysostaphine (par exemple, variantes et enzymes apparentées) démontrent une activité similaire.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5347097P | 1997-07-23 | 1997-07-23 | |
US60/053,470 | 1997-07-23 | ||
PCT/US1998/015257 WO1999004809A1 (fr) | 1997-07-23 | 1998-07-21 | Compositions pharmaceutiques renfermant de la lysostaphine seule ou en combinaison avec un antibiotique pour le traitement des infections staphylococciques |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2297083A1 CA2297083A1 (fr) | 1999-02-04 |
CA2297083C true CA2297083C (fr) | 2007-10-30 |
Family
ID=21984478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002297083A Expired - Fee Related CA2297083C (fr) | 1997-07-23 | 1998-07-21 | Compositions pharmaceutiques renfermant de la lysostaphine seule ou en combinaison avec un antibiotique pour le traitement des infections staphylococciques |
Country Status (20)
Country | Link |
---|---|
US (1) | US20020006406A1 (fr) |
EP (1) | EP1001804B1 (fr) |
JP (1) | JP2001510805A (fr) |
KR (1) | KR20010022237A (fr) |
CN (1) | CN1269727A (fr) |
AT (1) | ATE316794T1 (fr) |
AU (1) | AU754806B2 (fr) |
BR (1) | BR9811535A (fr) |
CA (1) | CA2297083C (fr) |
DE (1) | DE69833377T2 (fr) |
HU (1) | HUP0002662A3 (fr) |
IL (1) | IL134056A0 (fr) |
NO (1) | NO320884B1 (fr) |
NZ (1) | NZ502359A (fr) |
PL (1) | PL338178A1 (fr) |
RU (1) | RU2234940C2 (fr) |
SK (1) | SK732000A3 (fr) |
TW (1) | TWI235656B (fr) |
WO (1) | WO1999004809A1 (fr) |
ZA (1) | ZA986593B (fr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399098B1 (en) | 1997-10-31 | 2002-06-04 | New Horizons Diagnostics Corp | Composition for treating dental caries caused by streptococcus mutans |
US6056954A (en) | 1997-10-31 | 2000-05-02 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses |
US6432444B1 (en) | 1997-10-31 | 2002-08-13 | New Horizons Diagnostics Corp | Use of bacterial phage associated lysing enzymes for treating dermatological infections |
US6428784B1 (en) | 1997-10-31 | 2002-08-06 | New Horizons Diagnostics Corp | Vaginal suppository for treating group B Streptococcus infection |
US6423299B1 (en) | 1997-10-31 | 2002-07-23 | Vincent Fischetti | Composition for treatment of a bacterial infection of an upper respiratory tract |
US6277399B1 (en) | 1997-10-31 | 2001-08-21 | New Horizon Diagnostics Corporation | Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections |
US7232576B2 (en) | 1997-10-31 | 2007-06-19 | New Horizons Diagnostics Corp | Throat lozenge for the treatment of Streptococcus Group A |
US6406692B1 (en) | 1997-10-31 | 2002-06-18 | New Horizons Diagnostics Corp | Composition for treatment of an ocular bacterial infection |
US6399097B1 (en) | 1997-10-31 | 2002-06-04 | New Horizons Diagnostics Corporation | Composition for treatment of a bacterial infection of the digestive tract |
US6569830B1 (en) | 1999-03-05 | 2003-05-27 | Ambi, Inc. | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
US20020127215A1 (en) * | 1999-09-14 | 2002-09-12 | Lawrence Loomis | Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections |
US20020187136A1 (en) * | 2000-04-28 | 2002-12-12 | Lawrence Loomis | Use of bacterial phage associated lysing enzymes for treating various illnesses |
US6395504B1 (en) | 2000-09-01 | 2002-05-28 | New Horizons Diagnostics Corp. | Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants |
EP1494614A4 (fr) * | 2002-03-26 | 2010-08-11 | Biosynexus Inc | Rupture par enzymes de biofilms bacteriens |
AU2003298770A1 (en) * | 2002-12-02 | 2004-06-23 | Biosynexus Inc | Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
EA200500804A1 (ru) * | 2002-12-10 | 2005-12-29 | Биосинексус Инкорпорейтед | Топические противоинфекционные композиции |
US20100221237A1 (en) * | 2003-03-26 | 2010-09-02 | Biosynexus Incorporated | Enzyme disruption of bacterial biofilms |
MX2007008358A (es) * | 2005-01-10 | 2007-09-06 | Nabi Biopharmaceuticals | Metodo para tratar la infeccion con staphylococcus aureus. |
US8273339B2 (en) * | 2005-04-12 | 2012-09-25 | Nektar Therapeutics | Polymer-based compositions and conjugates of antimicrobial agents |
EP2004215B1 (fr) | 2006-03-31 | 2010-06-09 | The University Court of the University of St. Andrews | Compositions antimicrobiennes comprenant un peptide cationique et une endopeptidase de glycylglycine |
CA2651125C (fr) * | 2006-05-05 | 2016-06-28 | Gangagen, Inc. | Activites antimicrobiennes derivees de bacteriophages |
US20110044968A1 (en) * | 2008-03-10 | 2011-02-24 | Pharmal N Corporation | Compositions for treatment with metallopeptidases, methods of making and using the same |
WO2009150171A1 (fr) * | 2008-06-10 | 2009-12-17 | Profos Ag | Procédé de traitement de maladies inflammatoires |
CN105579053B (zh) | 2013-08-06 | 2021-08-31 | 达特茅斯学院理事会 | 非糖基化溶葡球菌素变体蛋白 |
RU2572341C2 (ru) * | 2013-09-20 | 2016-01-10 | Федеральное государственное бюджетное учреждение Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) | АНТИБИОТИК ИНА 5812, ШТАММ-ПРОДУЦЕНТ Streptomyces roseoflavus ИНА-Ас-5812 И СПОСОБ ПОЛУЧЕНИЯ АНТИБИОТИКА |
WO2019059804A1 (fr) * | 2017-09-25 | 2019-03-28 | Георгий Георгиевич ЧУМБУРИДЗЕ | Composition thermostable possédant une action antivirale et antibactérienne, et utilisation de celle-ci |
US11565024B2 (en) | 2017-11-16 | 2023-01-31 | Georgia Tech Research Corporation | Lysostaphin containing synthetic hydrogel carriers for bone repair |
CN110917339B (zh) * | 2019-12-27 | 2023-07-07 | 遵义医学院附属医院 | 一种溶葡萄球菌酶凝胶剂及其在mrsa感染创面中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858962A (en) * | 1987-05-11 | 1999-01-12 | Ambi Inc. | Composition for treating mastitis and other staphylococcal infections |
AU623864B2 (en) * | 1988-08-29 | 1992-05-28 | Applied Microbiology, Inc | Method of treating mastitis and other staphylococcal infections |
-
1998
- 1998-07-21 DE DE69833377T patent/DE69833377T2/de not_active Expired - Lifetime
- 1998-07-21 BR BR9811535-9A patent/BR9811535A/pt not_active IP Right Cessation
- 1998-07-21 PL PL98338178A patent/PL338178A1/xx not_active Application Discontinuation
- 1998-07-21 SK SK73-2000A patent/SK732000A3/sk unknown
- 1998-07-21 RU RU2000104516/15A patent/RU2234940C2/ru not_active IP Right Cessation
- 1998-07-21 JP JP2000503861A patent/JP2001510805A/ja active Pending
- 1998-07-21 NZ NZ502359A patent/NZ502359A/en unknown
- 1998-07-21 IL IL13405698A patent/IL134056A0/xx unknown
- 1998-07-21 CA CA002297083A patent/CA2297083C/fr not_active Expired - Fee Related
- 1998-07-21 HU HU0002662A patent/HUP0002662A3/hu unknown
- 1998-07-21 CN CN98808669A patent/CN1269727A/zh active Pending
- 1998-07-21 AT AT98935954T patent/ATE316794T1/de not_active IP Right Cessation
- 1998-07-21 KR KR1020007000810A patent/KR20010022237A/ko not_active Application Discontinuation
- 1998-07-21 AU AU85095/98A patent/AU754806B2/en not_active Ceased
- 1998-07-21 WO PCT/US1998/015257 patent/WO1999004809A1/fr not_active Application Discontinuation
- 1998-07-21 US US09/120,030 patent/US20020006406A1/en not_active Abandoned
- 1998-07-21 EP EP98935954A patent/EP1001804B1/fr not_active Expired - Lifetime
- 1998-07-23 ZA ZA986593A patent/ZA986593B/xx unknown
- 1998-08-29 TW TW087112047A patent/TWI235656B/zh not_active IP Right Cessation
-
2000
- 2000-01-21 NO NO20000314A patent/NO320884B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
NO20000314D0 (no) | 2000-01-21 |
NZ502359A (en) | 2005-02-25 |
HU0002662D0 (en) | 2000-08-28 |
WO1999004809A1 (fr) | 1999-02-04 |
JP2001510805A (ja) | 2001-08-07 |
IL134056A0 (en) | 2001-04-30 |
EP1001804A1 (fr) | 2000-05-24 |
TWI235656B (en) | 2005-07-11 |
CA2297083A1 (fr) | 1999-02-04 |
DE69833377D1 (de) | 2006-04-13 |
BR9811535A (pt) | 2000-08-29 |
KR20010022237A (ko) | 2001-03-15 |
NO320884B1 (no) | 2006-02-06 |
HUP0002662A2 (hu) | 2000-12-28 |
PL338178A1 (en) | 2000-10-09 |
AU8509598A (en) | 1999-02-16 |
CN1269727A (zh) | 2000-10-11 |
DE69833377T2 (de) | 2006-11-16 |
HUP0002662A3 (en) | 2003-08-28 |
RU2234940C2 (ru) | 2004-08-27 |
AU754806B2 (en) | 2002-11-28 |
US20020006406A1 (en) | 2002-01-17 |
EP1001804B1 (fr) | 2006-02-01 |
SK732000A3 (en) | 2001-03-12 |
ATE316794T1 (de) | 2006-02-15 |
NO20000314L (no) | 2000-03-16 |
ZA986593B (en) | 1999-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2297083C (fr) | Compositions pharmaceutiques renfermant de la lysostaphine seule ou en combinaison avec un antibiotique pour le traitement des infections staphylococciques | |
US7572439B2 (en) | Enzyme disruption of bacterial biofilms | |
US8198231B2 (en) | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains | |
US6028051A (en) | Method for the treatment of staphylococcal disease | |
US20140314823A1 (en) | Antimicrobial peptides | |
US20100221237A1 (en) | Enzyme disruption of bacterial biofilms | |
EP1671644A2 (fr) | Compositions pharmaceutiques contenant uniquement ou en combinaison avec un antibiotique de la lysostaphin pour le traitement des infections à staphylocoques | |
CA3088890A1 (fr) | Compositions de bacteriophages pour le traitement d'infections a pseudomonas | |
US20220160842A1 (en) | Method of treating infective endocarditis | |
AU2004201269B2 (en) | A method for the treatment of staphylocccal disease | |
CA3136461A1 (fr) | Methode de traitement et de prevention d'infections osseuses et articulaires | |
CZ2000144A3 (cs) | Farmaceutické kompozice obsahující lysostafin, samotné nebo v kombinaci s antibiotikem, pro léčbu stafylokokových infekcí | |
US20210252083A1 (en) | Bacteriophage compositions for treating staphylococcus infection | |
US20240189373A1 (en) | Bacteriophage compositions for treating staphylococcus infection | |
Rose et al. | In Vitro Activity of Nisin and Evaluation of Guar Gum as A Potential Drug Delivery System against Methicillin-Resistant Staphylococcus aureus Isolated from Diabetic Foot Ulcers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20150721 |